Several phase II clinical trials have examined the potential benefits of adding either mTOR inhibitors (Rapa, everolimus, tenolimus) or HCQ (autophagy-lysosome inhibitor) to conventional chemotherapy in the treatment of patients with malignant gliomas [36, 37], non-Hodgkin lymphomas [38], sarcoma [39], melanoma [15, 16], breast [40], non-small cell lung [41, 42], esophageal [43], and head and neck cancers [44]. This evidence concerns the gene MTOR and malignant glioma.